BioLife Solutions, Inc. (NASDAQ:BLFS) Closed 22.4% Above Its 50 Day Average


It is trading at $6.62 significantly higher than $5.41, the stock’s 50 day moving average and a great deal higher than the 200 day moving average of $3.50. The 50 day moving average moved up $1.21 whereas the 200 day moving average was up $3.12 or +89.11%. 174K shares changed hands in the last trading session. Volume was up 979.46% over the stocks average daily volume.

Traders are feeling more bearish on the company lately as implied by the uptick in short interest. The stock experienced a rise in short interest of 3.56% as of the latest report on September 29, 2017. Short shares grew 20,656 over that period. Days to cover decreased -2.0 to 2.0 and the short interest percentage is 0.05% as of September 29.

These funds have shifted positions in (BLFS). Price T Rowe Associates Inc /md/ augmented its holdings by buying 1,400 shares an increase of 9.0% from 03/31/2017 to 06/30/2017. Price T Rowe Associates Inc /md/ now holds 16,900 shares with a value of $40,000. The value of the position overall is up by 25.0%. As of quarter end Morgan Stanley had sold 3 shares trimming its stake by 16.7%. The value of the investment in BioLife Solutions, Inc. went from $0 to $0 decreasing nan% since the last quarter.

Blackrock Inc. cut its position by selling 29,481 shares a decrease of 89.2% as of 06/30/2017. Blackrock Inc. currently owns 3,558 shares worth $9,000. The total value of its holdings decreased 87.0%. Ubs Group Ag reduced its investment by shedding 205 shares a decrease of 60.5%. Ubs Group Ag owns 134 shares valued at $0. The total value of its holdings decreased 100.0%.

In the latest earnings report the EPS was $-0.46 and is expected to be $-0.24 for the current year with 13,228,000 shares outstanding. Next quarter’s EPS is forecasted at $-0.06 and the next full year EPS is projected to be $-0.05.

BioLife Solutions, Inc. (BioLife), launched on March 25, 1998, is involved in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage, and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers. The Business’s product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues and organs; generic blood stem cell freezing and cell thawing media products; custom product formulation and custom packaging services; cold chain logistics services incorporating precision thermal packaging products and cloud-hosted Web applications, and contract aseptic manufacturing formulation, fill and finish services of liquid media products..